

ASX Release

Investor Presentation

PERTH, AUSTRALIA – 17 November 2020: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that Dr Michael Baker is presenting at the Finance News Network Virtual Investor Event on 17 November, 2020.

A copy of the Investor Presentation follows.

For and on behalf of the Board and for further information please contact:

Dr Michael Baker Chief Executive Officer & Managing Director SUDA Pharmaceuticals Ltd Tel +61 (0) 403 468 187 mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist[®] technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist[™], a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit <u>www.sudapharma.com</u>



SUDA PHARMACEUTICALS LTD

Finance News Network Virtual Investor Event

Dr Michael Baker November 2020

Disclaimer

The purpose of the presentation is to provide an update of the business of SUDA PHARMACEUTICALS LTD (ASX:SUD) ['SUDA']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by SUDA and should not be relied upon as an independent source of information. Please contact SUDA and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside SUDA's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and SUDA's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.


This presentation should not be relied on as a recommendation or forecast by SUDA. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



Company Highlights

- Refreshed Board and Management Team: Actively seeking new deal flow for technologies with a focus on oncology and the central nervous system
- Unique Platform Technology OroMist[™]: Reformulate existing billion-dollar drugs for oral delivery, faster path to market, which can create cost and time savings
- TGA Approval Secured for ZolpiMist: ZolpiMist received TGA approval July 2020 for the treatment of short-term insomnia – assists licensed territories covering 550 million people
- Large Target Markets: Cancer (US\$38b for immunooncology by 2025) insomnia (US\$4b by 2026), migraine (US\$8.7b by 2026), and medical grade cannabis (US\$51b by 2025)
- Oversubscribed Entitlement Offer: We have strong support from shareholders, and we will continue to ensure we our prioritise our shareholders

Focus – Oncology and CNS







Technology Highlights - OroMist™

Clinical Data¹ Demonstrates:

- Increased Bioavailability
- The drug bypasses the gastro-intestinal tract preventing breakdown so patient's can potentially take less drug

Faster onset of action:

 The drug can enter the blood stream directly by crossing the lining of the mouth


Easier to administer:

- Patients suffering from nausea may be able to effectively take their medication
- Patients not amenable to taking medication can be treated – i.e. seizure, dysphagia, paediatrics

Increased Compliance:

 An oral spray removes the need for injection and the requirement to swallow or inhale

The most effective drug dosing methods



Source: Physician's Desk Reference, NPPDR, No. 18:676, 1997

1. Clinical data available for Estradiol, Clemastine fumarate, Sildenafil and Loratadine.



IP & Platform Strategy

INTELLECTUAL PROPERTY

- Multiple patent families covering:
 - Many high-usage existing drugs formulated into oral sprays
 - Hydrotrope technology for better delivery of drugs across the oral mucosa
 - Anagrelide use in cancer granted in Europe, Japan and Australia
 - We will continue to secure additional IP

PLATFORM TECHNOLOGY

- Core in-house competence in oro-mucosal reformulation
- Established process development and scale-up expertise



Current Treatments: Pain Relief Pulmonary Insomnia Arterial Hypertension **Epilepsy** Migraine Malaria Cancer **Chemo-induced** Erectile Anxiety Nausea Dysfunction



Pharmaceutical Partnership Strategy





Mitsubishi Tanabe Pharma






Cann Pharmaceutical



Business Strategy - Develop and License



ZolpiMist - Insomnia

- ZolpiMist is SUDA's spray version of the insomnia drug Ambien - Sanofi's blockbuster insomnia treatment
- Licensed territories covering 550 million people
- SUDA has rest-of-world rights ex-North America¹, and has licensed the product to Teva and Mitsubishi Tanabe Pharma Singapore and MTP Korea
- Therapeutics Goods Administration (TGA) approval received July 2020
- TGA approval will assist our partners with their regulatory submissions and commercialisation efforts
- Secure Australian partner for the commercialisation of ZolpiMist
- Discussions with additional territories are underway

1. Aytu BioScience holds the licence For ZolpiMist covering North America



TEVA PHARMACEUTICALS



Mitsubishi Tanabe Pharma





Anagrelide - Reformulating to Treat Cancer



- Anagrelide: An approved generic drug to treat a rare blood disorder
- Research Shows: Cancer patients with high platelet counts have a poor prognosis and lowering platelets may increase survival rates
- Making Anagrelide Safer: The capsule has unwanted side effects on the heart, and an injectable formulation does not exist
- Preclinical Animal Studies Demonstrate: An oral spray may reduce exposure to the cardiostimulatory metabolite
- Reformulation Work: Conversion into an oral spray is ongoing
- SUDA Owns Intellectual Property:
 - "Prevention and treatment of metastatic disease in thrombocytotic cancer patients"
 - Granted in Europe, Japan and Australia
- We Have The Team: Dr Richard Franklin is the Project Director, involved in progressing Agrylin[®] through to approval throughout Europe



Project Director

Dr Richard Franklin


Dr Franklin gained his PhD from Surrey University in the UK in Drug Metabolism and Pharmacokinetics. He has worked for several major drug companies including Glaxo, Wyeth, Sterling Winthrop, & AstraZeneca. He was head of New Product Innovation at Shire Pharmaceuticals and involved in the development and registration of anagrelide for the treatment of essential thrombocythemia in Europe.



Expanding our Portfolio

- SUDA has a refreshed board and senior management team
- The team has expertise in sourcing, evaluating and acquiring novel technologies
- SUDA's key areas of focus are oncology and the central nervous system
- SUDA will continue to source deal flow and add new technologies to the portfolio in the oncology and CNS space

Oncology



Central Nervous System





Board & Senior Management



Paul Hopper

Over 25 years experience in the medical, healthcare & life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director or CEO, of more than fourteen companies in the US, Australia and Asia. Mr Hopper has founded, or technology seeded, four companies on the ASX.





Dr. Michael Baker

Over 15 years experience in scientific research, drug development and venture investing sectors. He was an Investment Manager with the leading Australian life science fund, BioScience Managers, responsible for deal sourcing from networks, conferences, universities and research institutes. He also conducted due diligence to shortlist investment opportunities and played an active role in managing portfolio companies.





Executive Director

David Phillips

Senior Business Development Executive with over 35 years in the healthcare industry. Including 23 years in GSK, 12 years in Biotech and as Managing Partner of SR One (GlaxoSmithKline's Corporate Venture Fund). During this period Mr Phillips was a member of the investment committee reviewing greater than 30 deals. David has been responsible for over 50 Pharma/Biotech deals and 10M&A transactions.





David Simmonds

David was a Senior Audit Partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. David was a member of the Board of MS Research Australia.




Strategic Future

- Source, Evaluate and Acquire new technologies
- Continue to expand the team with deep Biotechnology/Drug Development/Pharma experience
- Build out the intellectual property portfolio patents and knowhow
- Build out the OroMist platform to reformulate existing billion-dollar drugs for oral delivery
- Create additional big pharma partnerships such as Teva, Sanofi and Mitsubishi
- We have strong support from our current shareholders and we will continue to ensure that our shareholders are prioritised









SUDA PHARMACEUTICALS LTD

The CFO Solution Level 3 62 Lygon Street Carlton VIC 3053

(T) +61 8 6142 5555 (F) +61 8 9443 8858

CONTACT

Dr Michael Baker CEO & Managing Director Email: mbaker@sudapharma.com Mobile: +61 403 468 187